◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › IXHL

Incannex Healthcare Inc. (IXHL) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-07-09

Incannex Healthcare Inc. (IXHL) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Sydney, Australia with about 12 employees. Its market capitalization is roughly $40 million.

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia.

Interactive charts & full statements →

IXHL Revenue & Earnings History — Annual Income Statement

Income statement2025-06-302024-06-302023-06-302022-06-30
Total Revenue$0M$0M$0M
Gross Profit$0M$0M
Operating Income (EBIT)($19M)($14M)($10M)
Net Income($18M)($49M)($10M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IXHL Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Revenue$0M$0M$0M$0M$0M
Operating Income (EBIT)($4M)($6M)($6M)($5M)($4M)
Net Income($4M)($6M)($6M)($4M)($6M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IXHL Free Cash Flow History

IXHL Balance Sheet History

Balance sheet2025-06-302024-06-302023-06-302022-06-30
Total Assets$17M$24M$26M
Total Liabilities$6M$3M$1M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive IXHL viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

← IVZAll stocksIZEA →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.